Effect of different dosing regimens of exon skipping antisense oligonucleotides on functional outcome in the mdx mouse model of Duchenne muscular dystrophy

被引：0
|
作者：
Datson, N. [1 ]
Weij, R. [1 ]
Bijl, S. [1 ]
Janson, A. [1 ]
Vermue, R. [1 ]
Testerink, J. [1 ]
van Deutekom, J. [1 ]
机构：
[1] BioMarin, Leiden, Netherlands
来源：
NEUROMUSCULAR DISORDERS | 2015年 / 25卷
关键词：
D O I：
10.1016/j.nmd.2015.06.375
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
G.P.351
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [41] Beyond clinical trials for antisense-mediated exon skipping for Duchenne muscular dystrophy
    Aartsma-Rus, Annemieke
    HUMAN GENE THERAPY, 2014, 25 (11) : A13 - A13
  • [42] Phase 1/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy
    Komaki, Hirofumi
    Takeshita, Eri
    Kunitake, Katsuhiko
    Ishizuka, Takami
    Shimizu-Motohashi, Yuko
    Ishiyama, Akihiko
    Sasaki, Masayuki
    Yonee, Chihiro
    Maruyama, Shinsuke
    Hida, Eisuke
    Aoki, Yoshitsugu
    CELL REPORTS MEDICINE, 2025, 6 (01)
  • [43] Exon 53 skipping of the human dystrophin transcript with different chemically modified AONs in a mouse model for Duchenne muscular dystrophy
    Engelbeen, Sarah
    O'Reilly, Daniel
    Van De Vijver, Davy
    Verhaart, Ingrid
    van Putten, Maaike
    Hariharan, Vignesh
    Khvorova, Anastasia
    Aartsma-Rus, Annemieke
    Damha, Masad
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 515 - 516
  • [44] THE MDX MOUSE MYOPATHY AS A MODEL DUCHENNE MUSCULAR-DYSTROPHY
    COULTON, G
    CURTIN, N
    MORGAN, J
    PARTIDGE, T
    SLOPER, J
    JOURNAL OF PATHOLOGY, 1987, 151 (01): : A92 - A92
  • [45] The aging mdx mouse as a model of cardiomyopathy for Duchenne muscular dystrophy
    Hoey, A
    van Erp, C
    Laws, N
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (01) : 174 - 174
  • [46] Respiratory Control in the mdx Mouse Model of Duchenne Muscular Dystrophy
    Burns, David P.
    Edge, Deirdre
    O'Malley, Dervla
    O'Halloran, Ken D.
    ARTERIAL CHEMORECEPTORS IN PHYSIOLOGY AND PATHOPHYSIOLOGY, 2015, 860 : 239 - 244
  • [47] Optimization of Antisense Oligonucleotide Drugs for Skipping Dystrophin Exon 51 and 53 in Duchenne Muscular Dystrophy
    Wu, Bo
    MOLECULAR THERAPY, 2018, 26 (05) : 148 - 148
  • [48] Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy
    Chwalenia, Katarzyna
    Wood, Matthew J. A.
    Roberts, Thomas C.
    JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, 2025,
  • [49] The Pharmacokinetics of 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy
    Bosgra, Sieto
    Sipkens, Jessica
    de Kimpe, Sjef
    den Besten, Cathaline
    Datson, Nicole
    van Deutekom, Judith
    NUCLEIC ACID THERAPEUTICS, 2019, 29 (06) : 305 - 322
  • [50] Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)Clinical Development for Duchenne Muscular Dystrophy
    Verheul, Ruurd C.
    van Deutekom, Judith C. T.
    Datson, Nicole A.
    PLOS ONE, 2016, 11 (09):
12345